暴露前狂犬病疫苗接种的免疫原性:剂量数与给药途径比较的系统综述与Meta分析
该系统综述与Meta分析比较了暴露前狂犬病疫苗一剂、两剂、三剂方案及肌内与2位点皮内途径的免疫应答。共纳入54项研究,短期多数两剂或三剂接种者无论途径均达到≥0.5 IU/mL滴度,一剂方案血清转化与GMT显著较低;两剂肌内方案长期血清转化维持低于三剂肌内方案;加强后几乎所有接种者血清转化。
要点
- 短期两剂或三剂方案无论肌内或2位点皮内途径,多数接种者达到≥0.5 IU/mL。
- 一剂方案短期和长期血清转化显著降低。
- 两剂肌内方案长期血清转化维持低于三剂肌内方案。
核心结论
- 两剂和三剂方案在短期及加强后血清转化相似,无论给药途径。
- 两剂肌内方案长期血清转化维持低于三剂肌内方案。
- 一剂方案短期和长期血清转化显著降低。
- 所有方案免疫应答随时间下降,但加强后几乎所有接种者血清转化。
- 2位点皮内与肌内给药应答总体相似,仅少数差异。
研究设计与样本
- 系统综述与Meta分析,利用现有系统综述并在三个数据库更新检索至2024年1月15日。
- 共纳入54项符合标准的研究。
- 对直接比较研究、同一参与者/组内方案比较及跨研究臂合并数据进行血清转化(≥0.5 IU/mL)和几何平均滴度(GMT)的Meta分析。
主要发现
- 短期多数接受两剂或三剂者达到滴度≥0.5 IU/mL,无论给药途径;一剂方案血清转化和GMT显著较低。
- 所有方案滴度随时间下降,两剂肌内方案血清转化维持低于三剂肌内方案。
- 加强后所有方案GMT升至高于初免系列,血清转化几乎达100%,初免为一剂2位点皮内者血清转化最低(98.7%)。
- 肌内与2位点皮内给药比较,血清转化一般无显著差异,GMT差异有限。
关键数值与推荐
- 血清转化阈值定义为≥0.5 IU/mL。
- 初免为一剂2位点皮内者加强后血清转化最低(98.7%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Human rabies is rare, though almost universally fatal. Rabies pre-exposure prophylaxis (PrEP) simplifies the post-exposure prophylaxis regimen and may offer some protection from unrecognized rabies exposures. Several different PrEP schedules are recommended by different jurisdictions. The objective of this review was to systematically analyze the impact of schedule and route of administration on immune responses to rabies vaccine in the short-term, long-term, and post-booster, specifically comparing one-, two-, and three-dose schedules, and intramuscular (IM) and 2-site intradermal (ID) routes of administration. METHODS: An existing systematic review was leveraged, and an updated search was conducted in three databases from inception to January 15, 2024. Meta-analyses of seroconversion (≥0.5 IU/mL) and geometric mean titres (GMTs) from direct comparison studies, studies which allowed comparisons of schedules within the same participants/groups of participants, and pooled data across study arms were conducted. RESULTS: Fifty-four studies met the eligibility criteria. Short-term, most participants who received two or three doses achieved titres ≥0.5 IU/mL regardless of route of administration; seroconversion and GMTs were significantly lower with one-dose schedules. Titres fell over time for all schedules with lower maintenance of seroconversion for two-dose IM schedules than three-dose IM schedules. Following the administration of booster doses, all schedules boosted to GMTs higher than after the primary series resulting in almost 100 % seroconversion, with the lowest seroconversion (98.7 %) for those who received a one 2-site ID dose for their primary vaccination. When comparing IM to 2-site ID administration of rabies vaccine, generally, no significant differences in seroconversion and limited differences in GMTs were observed. CONCLUSION: Two- and three-dose schedules had similar seroconversion regardless of route of administration in the short-term and after the booster, but two doses given IM resulted in lower maintenance of seroconversion in the long-term than three doses IM. Seroconversion was significantly reduced with a one-dose schedule in the short- and long-term. Immune responses to all schedules decreased over time, but almost all participants seroconverted following a booster dose. Responses between 2-site ID and IM administration were generally similar with only a few differences observed.
引用
- Davis P, Montroy J, Warshawsky B, et al. Immunogenicity of pre-exposure rabies vaccination comparing number of doses and routes of administration: A systematic review and meta-analyses. Vaccine. 2025. PMID: 40081151. doi:10.1016/j.vaccine.2025.126878
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。